India-focused private equity firm ChrysCapital has acquired a ten percent stake in India-based contract research and discovery services company GVK Biosciences from Sequoia Capital for US$25 million. ChrysCapital has also reportedly committed additional funds to back GVK Biosciences’ plans to grow through acquisitions. The transaction, which recently received Foreign Investment Promotion Board approval, valued the company at US$250 million.